Clinical trial registry record

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 20, 2018.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03468296
Last registry update
April 20, 2018
Status
Unknown
Phase
Phase 4
Sponsor
Tennessee Retina
Enrollment
22
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
22
Population
ALL · 50 Years
Duration
2018-04-01 to 2019-07-01
Intervention
Intravitreal Aflibercept Injection 2mg
Comparator
Treat-And-Extend Treatment
Outcomes measured
Adverse Events — Through Week 14; Retinal Thickness — Weeks 14, 16, 24, 52; Subretinal Fluid Height — Weeks 14, 16, 24, 52; Pigment Epithelial Detachment Height — Weeks 14, 16, 24, 52; Proportion of Dry Maculas — Weeks 14, 16, 24, 52; Best-Corrected Visual Acuity — Weeks 14, 24, and 52; Change in Best-Corrected Visual Acuity — Weeks 14, 24, and 52; Proportion gaining >5 letters of Best-Corrected Visual Acuity — Weeks 14, 24, and 52; Treatment Burden — Through Week 52; Ability to Extend Treatment Interval — Through Week 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON